**INTRODUCTION**

Enterococci are increasingly encountered as significant pathogens, and have become a major cause of nosocomial infections. Moreover, multi-drug resistant enterococci including vancomycin-resistant enterococci have emerged, and now represent a major clinical problem. Antibiotic treatment of diseases caused by these organisms is complicated by intrinsic and acquired resistance to various antibiotics. Resistances to penicillin, vancomycin and high-level aminoglycosides are clinically important because they limit antibiotic treatment options.

A combination of cell wall active agents and aminoglycosides is recommended to achieve a synergistic bactericidal effect in enterococcal endocarditis and meningitis. Moreover, many infectious disease specialists use combination therapy for non-endocarditis bacteremia and other serious enterococcal infections, especially in critically ill patients. However, combination treatment is not applicable in cases of infection caused by enterococci with high-level aminoglycoside resistance. For this reason, it is important to establish the risk factors for enterococcal endocarditis and meningitis.
**MATERIALS AND METHODS**

**Patients**

All patients with positive blood cultures for *Enterococcus faecalis* and *Enterococcus faecium* between January 1999 and August 2003 were identified by a review of the computerized records of the Clinical Microbiology Laboratory of Seoul National University Hospital (Seoul, Republic of Korea), a 1500-bed tertiary care University Hospital and referral center. Patients of age 16 or older were included. Enterococcal bacteremia occurring 60 days or more after a previous episode in a patient that had already been registered was counted as a separate case and was included in the study (13). Medical records of the patients were retrospectively reviewed.

**Microbiological tests**

*Enterococcus* species were identified on the basis of 6.5% NaCl tolerance, bile-esculin hydrolysis, and growth rate at 45°C. Species were identified with the Vitek system (bio-Mérieux, Marcy l’Etoile, France), and by tests for motility, yellow pigmentation and methyl-α-D-glucopyranoside (14, 15). Antibiotic susceptibilities were determined by the disk diffusion method, following the recommendations of the Clinical and Laboratory Standards Institute (16). HRGR was determined by the disk diffusion method with 120 μg gentamicin discs (Oxoid Ltd., Basingstoke, UK) (16).

**Definitions**

*Clinically significant bacteremia* was defined as the isolation of enterococci from two or more separately obtained blood cultures, from a single blood culture and from a primary site, or from a single blood culture with a clinically apparent primary site.

*HLGR* was defined as a minimal inhibitory concentration of gentamicin exceeding 500 μg/mL (16).

*Polymicrobial bacteremia* was defined as the isolation from blood culture of one or more species of bacteria in addition to the enterococci (the same blood culture, or another blood culture within 24 hr of the initial culture that yielded enterococci). A single concomitant isolation of another bacterial species was deemed sufficient, except for coagulase-negative staphylococci, diphtheroids, α-hemolytic streptococci, and *Bacillus* species, which required isolation from two blood cultures.

Enterococcal bacteremia was considered to have been of *community-onset* if the enterococci were isolated from cultures of blood samples obtained within 48 hr of hospital admission (if the patient had not been transferred from another hospital), and if the patient had symptoms or signs suggestive of infection on admission. Otherwise, the enterococcal bacteremia was considered to be *nosocomial*.

**RESULTS**

**Enterococcus species in blood isolates**

We identified 215 cases of clinically significant *E. faecalis* and *E. faecium* bacteremia. One hundred and fifty (70%) were caused by *E. faecium* and 65 (30%) by *E. faecalis*. One hundred and thirty six (63%) were caused by enterococci with HLGR and 79 (37%) by enterococci without HLGR. The HLGR rate was 70% (105/150) in *E. faecium* and 48% (31/65) in *E. faecalis*.

Enterococci were isolated from two or more separately obtained blood cultures in 113 (53%) cases, from a single blood culture and from a primary site in 40 (19%) cases, and from a single blood culture with a clinically apparent primary site in 62 (29%) cases. Eight patients (two with *E. faecalis*, six with *E. faecium*) were re-enrolled because bacteremia caused by the same organism occurred again after 60 days.

**Clinical features of patients with bacteremia caused by HLGR**

The demographic, clinical features and outcomes of each group are shown in Table 1. The most common underlying disease in both groups was cancer, accounting for approximately 50% of cases. Two hundred six of the cases (96%) were
of bacteremia without endocarditis or meningitis. Nine cases (4%) of endocarditis and no cases of meningitis were detected. Hematologic malignancy, neutropenia, E. faecium infection, monomicrobial bacteremia and nosocomial infection were significantly more common in bacteremia caused by enterococci with HLGR than in bacteremia caused by enterococci without HLGR (P<0.05, in each case). On the other hand, biliary tract infection was less common in the former. Mean acute physiology and chronic health evaluation (APACHE) II scores were higher in bacteremia caused by enterococci with HLGR. Rates of resistance to ampicillin, vancomycin and high-level streptomycin were also higher in isolates of enterococci with HLGR (Table 2).

**Table 1.** Clinical features of 215 patients with bacteremia caused by enterococci with or without HLGR

| Variables                              | Number (%) of patients with bacteremia due to enterococci | P value |
|----------------------------------------|----------------------------------------------------------|---------|
|                                         | Without HLGR (n=79) | With HLGR (n=136) |
| Demographic data                       |               |                   |
| Male                                   | 52 (66)       | 92 (68)           | 0.784   |
| Age (yr)*                              | 58.1±14.2     | 56.2±16.8         | 0.389   |
| Underlying disease                     |               |                   |
| Cancer                                 | 42 (53)       | 70 (51)           | 0.811   |
| Hematologic malignancy                 | 4 (5)         | 27 (19)           | 0.003*  |
| Neutropenia                            | 4 (5)         | 39 (29)           | <0.001* |
| Solid organ transplantation             | 3 (4)         | 5 (4)             | >0.999  |
| Hemodialysis                           | 3 (4)         | 10 (7)            | 0.382   |
| Urologic disease                       | 5 (6)         | 7 (5)             | 0.763   |
| Primary site of infection              |               |                   |
| Biliary tract                          | 35 (44)       | 33 (24)           | 0.002*  |
| GI tract other than biliary tract      | 13 (16)       | 35 (26)           | 0.115   |
| Urinary tract                          | 12 (15)       | 20 (15)           | 0.923   |
| Vascular catheter                      | 2 (3)         | 12 (9)            | 0.071   |
| Infective endocarditis                 | 6 (8)         | 3 (2)             | 0.078   |
| Comorbid or predisposing condition     |               |                   |
| E. faecium infection                   | 45 (57)       | 105 (77)          | 0.002*  |
| Polymicrobial                          | 30 (38)       | 22 (24)           | <0.001* |
| Nosocomial                             | 51 (65)       | 115 (85)          | 0.001*  |
| APACHE II score*                       | 14.4±7.3      | 20.7±8.3          | <0.001* |
| ICU stay at culture                    | 7 (9)         | 36 (26)           | 0.002*  |
| Central venous catheter                | 10 (5)        | 41 (29)           | 0.004*  |
| Hospital-days before blood culture     | 16.9±22.8     | 33.6±47.5         | 0.004*  |
| Treatment and outcomes                 |               |                   |
| Appropriate antibiotic treatment       | 52 (66)       | 88 (65)           | 0.868   |
| 14-day mortality*                      | 12/78 (15)    | 50/135 (37)       | 0.001*  |
| 30-day mortality*                      | 17/76 (22)    | 66/133 (50)       | <0.001* |

*Statistically significant, P≤0.05.
*Continuous variables are expressed as means (±SD); *Expressed as number of deaths/number of patients followed up (%).

**Table 2.** Previous antibiotic use and antibiotic resistance in 215 patients with bacteremia caused by enterococci with or without HLGR

| Variables                              | Number (%) of patients with bacteremia due to enterococci | P value |
|----------------------------------------|----------------------------------------------------------|---------|
|                                         | Without HLGR (n=79) | With HLGR (n=136) |
| Previous antibiotic use                |               |                   |
| Penicillins                            | 12 (15)       | 46 (34)           | 0.003*  |
| 3rd generation cephalosporin           | 42 (53)       | 110 (81)          | <0.001* |
| Aminoglycoside                         | 30 (38)       | 93 (68)           | <0.001* |
| Quinolone                              | 12 (15)       | 44 (32)           | 0.006*  |
| Vancomycin                             | 4 (5)         | 26 (21)           | 0.002*  |
| Antibiotic resistance                  |               |                   |
| Ampicillin resistance                  | 18 (23)       | 107 (79)          | <0.001* |
| Vancomycin resistance                  | 1 (1)         | 18 (13)           | 0.003*  |
| High-level streptomycin resistance     | 18 (23)       | 82 (60)           | <0.001* |

*Statistically significant, P≤0.05.
HLGR, high-level gentamicin resistance.

**Table 3.** Associated factors for acquisition of bacteremia due to enterococci with HLGR determined by multivariate analysis using a logistic regression model

| Risk factors                              | Odds ratio (95.0% CI) | P value |
|-------------------------------------------|-----------------------|---------|
| Neutropenia                               | 6.17 (2.02-18.87)     | 0.001   |
| Monomicrobial bacteremia                  | 3.04 (1.50-6.17)      | 0.002   |
| ICU stay at culture                       | 3.44 (1.33-8.91)      | 0.011   |
| 3rd generation cephalosporin use         | 3.39 (1.74-6.61)      | <0.001  |

HLGR, High-level gentamicin resistance; ICU, Intensive care unit.

Risk factors for the acquisition of bacteremia caused by enterococci with HLGR

We performed multivariate analysis with a logistic regression model to identify the independent risk factors for the acquisition of bacteremia caused by enterococci with HLGR. The multivariate analysis included the following variables; hematologic malignancy, neutropenia, biliary tract infection, central venous catheter, intensive care unit (ICU) stay at time of culture, nosocomial infection, duration of hospital stay before bacteremia, monomicrobial infection, E. faecium infection, and previous use of penicillins, vancomycin, 3rd generation cephalosporin, aminoglycoside and quinolone. Multivariate analysis identified neutropenia, monomicrobial bacteremia, ICU stay at time of culture and use of 3rd generation cephalosporin as independent risk factors for bacteremia caused by enterococci with HLGR (Table 3).

**Influence of HLGR on mortality in patients with enterococcal bacteremia**

In univariate analysis, fourteen-day and 30-day mortalities...
Table 4. Independent risk factors for 30-day mortality in 209 episodes of enterococcal bacteremia, as determined by survival analysis using the Cox-regression model

| Risk factors                          | Odds ratio (95.0% CI) | P value |
|---------------------------------------|-----------------------|---------|
| Increasing APACHE II score*           | 1.08 (1.06-1.10)      | <0.001  |
| Bone marrow transplantation            | 4.27 (2.03-8.99)      | <0.001  |
| Corticosteroid use                     | 2.30 (1.38-3.82)      | 0.001   |
| Inappropriate antibiotic treatment     | 2.35 (1.49-3.70)      | <0.001  |

*Per 1 point increase in score.
APACHE, Acute physiology and chronic health evaluation.

were significantly higher in patients with bacteremia caused by enterococci with HLGR than in patients with bacteremia caused by enterococci without HLGR (37% vs. 15%, P = 0.001; 50% vs. 22%, P < 0.001; Table 1).

We performed multivariate analysis with the Cox-regression model to determine whether the difference in mortality was due to HLGR. The multivariate analysis included the following variables; biliary tract infection, hematologic malignancy, bone marrow transplantation, neutropenia, cancer chemotherapy, corticosteroid use, immunosuppressant use, *E. faecium* infection, APACHE II score, ampicillin resistance, vancomycin resistance, high-level gentamicin resistance and inappropriate antibiotic treatment. The analysis identified APACHE II score, bone marrow transplantation, corticosteroid use and inappropriate antibiotic treatment as independent risk factors for 30-day mortality (Table 4). When we controlled for these factors, the odds ratio for mortality due to bacteremia caused by enterococci with HLGR compared with bacteremia caused by enterococci without HLGR was 1.36, which was not statistically significant (95% confidence interval: 0.75-2.44).

**DISCUSSION**

Enterococci with HLGR comprised 63% of the enterococcal isolates that caused clinically significant bacteremia in our institute. In previous studies, the proportion of HLGR in blood isolates was 33-62% (7, 8, 10-12). Most isolates with HLGR were *E. faecalis* in the 1980s and early 1990s (10, 11). However, a recent study found almost the same rate of HLGR in *E. faecalis* and *E. faecium* blood isolates (12). HLGR was prevalent among enterococcal blood isolates in our study, as in previous studies. However, in our case the frequency of HLGR was significantly higher in *E. faecium* than in *E. faecalis*. Our data thus suggest that HLGR is now also prevalent in *E. faecium*. This may be due to the increase of multi-drug resistant *E. faecium* as the cause of nosocomial bacteremia (1, 18-20).

Some investigators have reported no connection between HLGR and the severity of the underlying disease or adverse outcome in enterococcal bacteremia (10, 11). On the other hand, others have reported higher mortality in patients with bacteremia caused by enterococci with HLGR (12). In the present study, we found that bacteremia caused by enterococci with HLGR was associated with more severe underlying disease and higher mortality than bacteremia caused by enterococci without HLGR. There are two possible explanations for the discrepancy between the studies. First, the predominant isolate differed; most of the blood isolates in the previous studies were *E. faecalis*, whereas the predominant blood isolate in our study was *E. faecium*. Although we observed the effects of HLGR on clinical features and outcomes in both *E. faecium* and *E. faecalis*, the differences were more prominent in *E. faecium* (data not shown). Second, it is possible that the sample sizes in the previous studies were too small to reveal the differences.

In previous studies, independent risk factors for the acquisition of bacteremia due to enterococci with HLGR were intensive care unit stay, previous use of antibiotics, especially broad-spectrum cephalosporin, chronic renal failure and *E. faecalis* species (8, 11). The results of our study are consistent with these findings; however, *E. faecalis* species was not a risk factor in our study. Two kinds of patients were at especially high risk of acquiring infections with HLGR enterococci in our study: patients with neutropenia and patients with intensive care unit stay. Our data suggest that the judicious use of 3rd generation cephalosporin is important to reduce infections caused by enterococci with HLGR, especially in patients belonging to these two groups.

There has been controversy over whether HLGR influences the prognosis of patients with enterococcal bacteremia. Watnakunakorn et al. and Caballero-Granado et al. reported that HLGR did not influence crude mortality from enterococcal bacteremia in 178 and 93 cases, respectively (10, 11). Shaked et al., however, recently reported that HLGR was an independent risk factor for mortality in 117 patients with enterococcal bacteremia (12). However, HLGR was associated with more severe underlying disease, resistance to other antibiotics and many comorbid conditions. Therefore confounding factors would need to be corrected for by an appropriate statistical model and an adequate sample size. It is possible that the sample size in the latter study was too small for the confounding factors to have been adequately corrected for in the multivariate analysis. In any event, in our study, which involved more cases than the previous studies, we found that HLGR did not significantly influence the outcome of enterococcal bacteremia.

The anatomical site of infection should be taken into account in treating enterococcal infection, because the appropriate treatment strategy differs for different sites. In cases of endocarditis or meningitis, combination therapy with a cell-wall active agent plus an aminoglycoside should be employed (4, 21). Antibiotic use in enterococcal infections without endocarditis or meningitis has been questioned because enterococci are traditionally considered to be pathogens of low virulence...
(22). However, there is some evidence that appropriate antibiotic use is associated with improved outcome in patients with enterococcal bacteremia (13). Combination therapy with a cell-wall active agent plus an aminoglycoside has also been considered in enterococcal bacteremia without endocarditis (5, 6), but in a number of studies there was no statistically significant difference in outcome between monotherapy and combination therapy (10, 23-25).

In our study, most of the cases were of enterococcal bacteremia without endocarditis or meningitis, and appropriate antibiotic treatment was associated with improved outcome. However, we also failed to obtain evidence that combination therapy was more effective. When we performed a multivariate analysis on 131 patients with enterococcal bacteremia who had received appropriate antibiotic treatment, monotherapy did not emerge as an independent risk factor for 30-day mortality (95% confidence interval: 0.72-5.79; \( P = 0.180 \)). It appears that prognosis of enterococcal bacteremia may be improved by appropriate antibiotic treatment rather than by giving combination antibiotic therapy.

Our study has some limitations. First, since it was retrospective in design, confounding factors which can affect mortality were not uniformly controlled. Because the factors influencing the physicians’ choice of antibiotics were not determined, they may have influenced our results as unmeasured confounding factors in the analysis. Second, we did not perform molecular epidemiologic studies such as pulsed-field gel electrophoresis to exclude outbreaks of specific strains or common sources of infection. Third, this was a single-center study and factors such as the rate of referrals or surgery for complex disorders could have impacted the results.

In conclusion, patients with HLGR enterococcal bacteremia were more likely to have severe underlying diseases and were associated with higher mortality than patients with non-HLGR enterococcal bacteremia. However, HLGR itself did not influence mortality in enterococcal bacteremia.

ACKNOWLEDGEMENT

We express our gratitude to the Medical Research Collaborating Center (MRCC) of Seoul National University Hospital for statistical consultation and review.

REFERENCES

1. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39: 309-17.

2. Lee K, Jang SJ, Lee HJ, Ryoo N, Kim M, Hong SG, Chong Y. Increasing prevalence of vancomycin-resistant enterococcus faecium, expanded-spectrum cephalosporin-resistant klebsiella pneumoniae, and imipenem-resistant pseudomonas aeruginosa in Korea: KON-SAR study in 2001. J Korean Med Sci 2004; 19: 8-14.

3. Lee K, Lee HS, Jung SJ, Park AJ, Lee MH, Song WK, Chong Y; Members of Korean Nationwide Surveillance of Antimicrobial Resistance Group. Antimicrobial resistance surveillance of bacteria in 1999 in Korea with a special reference to resistance of enterococci to vancomycin and gram-negative bacilli to third generation cephalosporin, imipenem, and fluoroquinolone. J Korean Med Sci 2001; 16: 262-70.

4. Murray BE. The life and times of the enterococcus. Clin Microbiol Rev 1990; 3: 46-65.

5. Wessels MR. Streptococcal and enterococcal infections. In: Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL, Loscalzo J, eds. Harrison’s principles of internal medicine, 17th ed. New York: McGraw-Hill 2008; 881-90.

6. Moellering RC Jr. Enterococcus species, Streptococcus bovis, and Leucostoc species. In: Mandell GL, Bennet JE, Dolin R, eds. Mandell, Douglas, and Bennett’s Principles and practice of infectious diseases, 6th ed. Philadelphia: Churchill Livingston 2005; 2411-21.

7. Noskin GA, Till M, Patterson BK, Clarke JT, Warren JR. High-level gentamicin resistance in Enterococcus faecalis bacteremia. J Infect Dis 1991; 164: 1212-5.

8. Huycke MM, Spiegel CA, Gilmore MS. Bacteremia caused by hemolytic, high-level gentamicin-resistant Enterococcus faecalis. Antimicrob Agents Chemother 1991; 35: 1626-34.

9. Wells WD, Wong ES, Murray BE, Coudron PE, Williams DS, Markowitz SM. Infections due to beta-lactamase-producing, high-level gentamicin-resistant Enterococcus faecalis. Ann Intern Med 1992; 116: 285-92.

10. Watanakunakorn C, Patel R. Comparison of patients with enterococcal bacteremia due to strains with and without high-level resistance to gentamicin. Clin Infect Dis 1993; 17: 74-8.

11. Caballero-Granado FJ, Cinseros JM, Luque R, Torres-Tortosa M, Gamboa F, Diez F, Villanueva JL, Perez-Cano R, Pasquaj J, Merino D, Menchero A, Mora D, Lopez-Ruz MA, Vergara A. Comparative study of bacteremias caused by Enterococcus spp. with and without high-level resistance to gentamicin. The Grupo Andaluz para el estudio de las Enfermedades Infecciosas. J Clin Microbiol 1998; 36: 520-5.

12. Shaked H, Carmeli Y, Schwartz D, Siegman-Igra Y. Enterococcal bacteremia: epidemiological, microbiological, clinical and prognostic characteristics, and the impact of high level gentamicin resistance. Scand J Infect Dis 2006; 38: 995-1000.

13. Vergis EN, Hayden MK, Chow JW, Snydman DR, Zervos MJ, Lindo PK, Wagener MM, Schmitt B, Muder RR. Determinants of vancomycin resistance and mortality rates in enterococcal bacteremia. a prospective multicenter study. Ann Intern Med 2001; 135: 484-92.

14. Facklam RR, Collins MD. Identification of Enterococcus species isolated from human infections by a conventional test scheme. J Clin Microbiol 1989; 27: 731-4.

15. Devriese LA, Pot B, Kersters K, Lauwers S, Haezebrock F. Acidification of methyl-alpha-D-glucopyranoside: a useful test to differentiate Enterococcus casseliflavus and Enterococcus gallinarum from Enterococcus faecium species group and from Enterococcus faecalis.
16. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing; eighteenth informational supplement. Wayne, PA: Clinical and Laboratory Standards Institute (CLSI), 2008; M100-S18.

17. Chow JW, Fine MJ, Shlaes DM, Quinn JP, Hooper DC, Johnson MP, Ramphal R, Wagener MM, Miyashiro DK, Yu VL. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991; 115: 585-90.

18. Handwerger S, Raucher B, Altarac D, Monka J, Marchione S, Singh KV, Murray BE, Wolff J, Walters B. Nosocomial outbreak due to Enterococcus faecium highly resistant to vancomycin, penicillin, and gentamicin. Clin Infect Dis 1993; 16: 750-5.

19. Boyle JF, Soumakis SA, Rendo A, Herrington JA, Gianarkis DG, Thurberg BE, Painter BG. Epidemiologic analysis and genotypic characterization of a nosocomial outbreak of vancomycin-resistant enterococci. J Clin Microbiol 1993; 31: 1280-5.

20. Boyce JM, Opal SM, Chow JW, Zervos MJ, Potter-Bynoe G, Sherman CB, Romulo RL, Fortna S, Medeiros AA. Outbreak of multidrug-resistant Enterococcus faecium with transferable vanB class vancomycin resistance. J Clin Microbiol 1994; 32: 1148-53.

21. Elliott TS, Foweraker J, Gould FK, Perry JD, Sandoe JA. Guidelines for the antibiotic treatment of endocarditis in adults: report of the Working Party of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother 2004; 54: 971-81.

22. Hoge CW, Adams J, Buchanan B, Sears SD. Enterococcal bacteremia: to treat or not to treat, a reappraisal. Rev Infect Dis 1991; 13: 600-5.

23. Graninger W, Ragette R. Nosocomial bacteremia due to Enterococcus faecalis without endocarditis. Clin Infect Dis 1992; 15: 49-57.

24. Gullberg RM, Homann SR, Phair JP. Enterococcal bacteremia: analysis of 75 episodes. Rev Infect Dis 1989; 11: 74-85.

25. Maki DG, Agger WA. Enterococcal bacteremia: clinical features, the risk of endocarditis, and management. Medicine (Baltimore) 1988; 67: 248-69.